Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
Neurourol Urodyn ; 27(6): 548-52, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18551561

RESUMEN

AIMS: To evaluate the usefulness of a quantification method using filter paper for analyzing minute voided urine of the mouse. METHODS: Voided stain on paper (VSOP) method; the correlation between area of stained spot on a filter paper and amount of applied liquid was calculated. Voiding behavior of the mice was analyzed by placing the animal above the same filter paper and recording voided time and area over 2 hr. The usefulness of the VSOP method was tested in analysis of the voiding behavior of five female 7-week-old ddY mice treated with cyclophosphamide (CPM, 150 mg/kg, intraperitoneally) and five control ones, in comparison with the histology of CPM-induced cystitis. Further, the voided volume of male and female ddY mouse ranging from 2 to 13 weeks was assessed. RESULTS: There was a linear correlation between liquid volume and stained area on the filter paper (y = 16.472x - 22.411, R(2) = 0.9981). Between control mice and those with histologically proven CPM cystitis, there was a significant difference in voided volume (362.7 +/- 51.9 and 127.8 +/- 100.0 microl, < 0.001) and voiding interval (10.30 +/- 3.10 and 4.47 +/- 1.70 min, < 0.001). Voided volume of ddY mice was quantifiable from as early as 2-week old, increased along with their growth and correlated well with their body weight [(voided volume: microl) = 10.8 x (body weight: g) + 32, R(2) = 0.762]. CONCLUSIONS: The VSOP method is a useful tool for evaluating voiding behavior of the mouse, including those with small bladder capacity.


Asunto(s)
Cistitis/fisiopatología , Papel , Vejiga Urinaria/fisiopatología , Micción , Urodinámica , Animales , Peso Corporal , Ciclofosfamida , Cistitis/inducido químicamente , Cistitis/patología , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Reproducibilidad de los Resultados , Factores de Tiempo , Vejiga Urinaria/crecimiento & desarrollo , Vejiga Urinaria/patología
2.
Clin Nephrol ; 70(6): 558-60, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19049718

RESUMEN

Induction of continuous ambulatory peritoneal dialysis (CAPD) as treatment of end-stage renal disease is difficult for patients requiring nephrectomy with traditional surgery, and usually hemodialysis is selected for these patients. In a 61-year-old woman with end-stage renal failure a left renal tumor was diagnosed by abdominal ultrasonography, enhanced computed tomography and magnetic resonance imaging. Following an urology consultation, we decided to perform left kidney nephrectomy. We estimated that she had to undergo dialysis permanently after nephrectomy. She desired to be treated by CAPD, however, we decided after allowing for a postoperative period for complete healing of the peritoneum to avoid complications. This is why during the interim period between surgery and induction of CAPD she underwent hemodialysis (HD) in a local outpatient HD center and in our hospital. We selected a retroperitoneoscopic approach for nephrectomy. Pathology evaluation revealed a renal cell carcinoma. 4 months after nephrectomy, CAPD catheter implantation was performed by using laparoscopy and CAPD was started. At the present time, the patient is doing well on CAPD. To our knowledge, there are no clear indications regarding initiation of peritoneal dialysis after nephrectomy. The retroperitoneoscopic approach for nephrectomy allows for initiation of peritoneal dialysis after nephrectomy within a relative short postoperative period.


Asunto(s)
Fallo Renal Crónico/terapia , Neoplasias Renales/cirugía , Laparoscopía/métodos , Nefrectomía/métodos , Diálisis Peritoneal Ambulatoria Continua/métodos , Cuidados Posoperatorios/métodos , Femenino , Estudios de Seguimiento , Humanos , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/diagnóstico , Neoplasias Renales/complicaciones , Neoplasias Renales/diagnóstico , Persona de Mediana Edad , Espacio Retroperitoneal , Tomografía Computarizada por Rayos X
3.
Transplant Proc ; 49(1): 41-44, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28104155

RESUMEN

BACKGROUND: Although kidney graft survival within 5 years after transplantation is now achieved in >95% of recipients, chronic graft deterioration remains a factor limiting long-term survival. Chronic nephrotoxicity induced by calcineurin inhibitors (CNIs) is one of the major causes of chronic graft injury; thus, minimization of CNIs by administration of everolimus (EVR) is expected to relieve their toxic effects. METHODS: Fifty-six kidney transplant recipients receiving CNI-based immunosuppression (tacrolimus, n = 34; cyclosporine, n = 22) were analyzed. The average posttransplant period at conversion was 7.4 years and no less than 3 years. Conversion of immunosuppression was accomplished by reducing CNI by 40% in dose and beginning EVR at 1 or 1.5 mg. Changes in graft function were examined, and adverse effects were evaluated. RESULTS: Significant improvement in graft function was observed quickly after EVR administration, and it had persisted for 1 year after conversion as a 7% increase in estimated glomerular filtration rate. No obvious acute rejection was observed. Further analyses concerning "timing of EVR conversion" and "graft function at conversion" were performed. Graft function was significantly improved even in patients with late conversion at 2 to 10 years. The estimated glomerular filtration rate was significantly improved even in patients with poor function. CONCLUSIONS: We concluded that this modification to the immunosuppressive regimen, as expected, reduced CNI nephrotoxicity. Our results showed that even patients with very late conversion or poor graft function also benefited from EVR conversion with CNI minimization.


Asunto(s)
Inhibidores de la Calcineurina/efectos adversos , Everolimus/administración & dosificación , Supervivencia de Injerto/efectos de los fármacos , Inmunosupresores/administración & dosificación , Trasplante de Riñón , Adulto , Inhibidores de la Calcineurina/administración & dosificación , Ciclosporina/administración & dosificación , Ciclosporina/efectos adversos , Quimioterapia Combinada , Femenino , Humanos , Terapia de Inmunosupresión/métodos , Inmunosupresores/efectos adversos , Riñón/efectos de los fármacos , Riñón/fisiopatología , Masculino , Persona de Mediana Edad , Tacrolimus/administración & dosificación , Tacrolimus/efectos adversos , Factores de Tiempo , Trasplantes/efectos de los fármacos , Adulto Joven
4.
Transplantation ; 66(12): 1708-13, 1998 Dec 27.
Artículo en Inglés | MEDLINE | ID: mdl-9884264

RESUMEN

BACKGROUND: One of the most serious problems facing major transplant programs is the severe shortage of organs. Expansion of the donor pool to include nontraditional donors, such as non-heart-beating donors (NHBDs), would considerably expand the availability of organs. METHODS: Between 1983 and 1996, we performed a total of 125 non-heart-beating cadaveric renal transplantations under cyclosporine-based or tacrolimus-based immunosuppression. Thirty-nine recipients were females and 86 were males. Total ischemic time (TIT) and warm ischemic time (WIT) were an average of 761+/-347 min (322-2027 min) and 7.4+/-13.1 min (0-45 min), respectively. RESULTS: Of the 125 transplanted kidneys from NHBDs, 98 (78.4%) developed delayed graft function (DGF), which lasted a mean of 16+/-21 days (range 3-37 days). One hundred and eight patients (86.4%) were off dialysis by the time of discharge. Of the 125 grafts, 11 (8.8%) were primary nonfunction. The average of the nadir of serum creatinine levels, which was evaluated using 108 patients who were off dialysis by the time of discharge, was 1.4+/-0.5 mg/dl. The lowest creatinine levels (nadir) were under 2.0 mg/dl in 98 (78.4%) of the 125 patients. Acute rejection occurred in 64 (51.2%) of the 125 recipients. Patient survival rates were 90% at 5 years and 88% at 10 years. Graft survival rates were 65% at 5 years and 46% at 10 years. We tried to find the risk factors that affected graft survival. We examined the various possible risk factors, including harvesting condition (controlled versus uncontrolled), HLA-AB mismatches, HLA-DR mismatches, graft weight, donor age and sex, recipient age and sex, posttransplant DGF, acute rejection, WIT, and TIT. However, no significant risk factor was identified except acute rejection. We tried to discover the risk factors that caused primary nonfunction. Possible risk factors, including donor age, TIT, WIT, graft weight, and harvesting condition were compared, but no significant risk factor was identified. Long-term renal function was evaluated by serum creatinine levels. Serum creatinine levels at 1, 5, and 10 years were 1.76+/-0.7 mg/dl, 1.7+/-0.96 mg/dl, and 1.53-/+0.6 mg/dl, respectively. CONCLUSIONS: In conclusion, our data demonstrated that the procurement of kidneys from NHBDs leads to acceptable long-term graft survival and renal function, despite a high incidence of DGF.


Asunto(s)
Trasplante de Riñón , Riñón/fisiopatología , Donantes de Tejidos , Adulto , Anciano , Femenino , Supervivencia de Injerto , Corazón/fisiología , Humanos , Trasplante de Riñón/mortalidad , Masculino , Persona de Mediana Edad , Factores de Riesgo , Trasplante Homólogo
5.
Hinyokika Kiyo ; 46(2): 123-6, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10769803

RESUMEN

An 83-year-old woman presented with left flank pain and high grade fever. After left ureteral catheterization and intensive chemotherapy with hemoperfusion, surgical exploration revealed the lower pole branches of the renal vessels were obstructing the ureteropelvic junction (UPJ), and dissection of the vessels released the obstruction. An 82-year-old man presented with right flank pain. Angiography demonstrated UPJ obstruction caused by the lower pole branch of the renal artery. Arterial dissection with dismembered pyeloplasty resulted in improvement of obstruction. In both cases, the patients had a long history of hypertension with mild to severe arteriosclerosis. Arteriosclerosis associated with fixation of the UPJ, may be one of the important factors leading to progressive hydronephrosis in geriatric patients.


Asunto(s)
Arteriosclerosis/complicaciones , Pelvis Renal , Arteria Renal , Obstrucción Ureteral/etiología , Anciano , Anciano de 80 o más Años , Arteriosclerosis/cirugía , Femenino , Humanos , Hidronefrosis/etiología , Pelvis Renal/cirugía , Masculino , Arteria Renal/cirugía , Resultado del Tratamiento , Obstrucción Ureteral/cirugía
6.
Hinyokika Kiyo ; 39(7): 645-8, 1993 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-8362684

RESUMEN

A case of multiple urinary stones in a patient with glycogen storage disease type 1 (GSD-1) is reported. In spite of the presence of hyperuricemia, these stones did not consist of uric acid, but mainly of calcium oxalate. Laboratory studies revealed distal renal tubular acidosis and hypocitraturia, but no significant abnormality in calcium metabolism. We discussed the mechanism of calcium stone formation in our case, and its prophylactic treatment by oral administration of citrate compound.


Asunto(s)
Acidosis Tubular Renal/complicaciones , Oxalato de Calcio/análisis , Enfermedad del Almacenamiento de Glucógeno Tipo I/complicaciones , Cálculos Urinarios/metabolismo , Adulto , Calcio/metabolismo , Humanos , Masculino , Cálculos Urinarios/química
7.
Hinyokika Kiyo ; 39(12): 1227-32, 1993 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-8285174

RESUMEN

A bisbenzylisoquinoline alkaloid, cepharanthine, significantly enhanced vinblastine, adriamycin and etoposide sensitivities in P-glycoprotein positive renal cancer cells. However, it did not show any enhancing effect on cisplatin sensitivity. Four patients with metastatic renal cell carcinomas were treated with intraarterial chemotherapy using vinblastine and/or adriamycin in combination with cepharanthine for their metastatic lesions (3 bone and 1 contralateral kidney metastases). A partial response was observed in 1 patient with femoral bone metastasis and a minor response in 1 patient with lumbar bone metastasis, although they were also treated with interferons. No adverse effects associated with cepharanthine were seen except in one patient complaining of redness and burning sense of the skin probably due to its vaso-dilatation effect.


Asunto(s)
Alcaloides/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Renales/tratamiento farmacológico , Neoplasias Renales/tratamiento farmacológico , Bencilisoquinolinas , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Carcinoma de Células Renales/secundario , Cisplatino/administración & dosificación , Doxorrubicina/administración & dosificación , Resistencia a Medicamentos , Humanos , Infusiones Intraarteriales , Neoplasias Renales/patología , Células Tumorales Cultivadas/efectos de los fármacos , Vinblastina/administración & dosificación
8.
Hinyokika Kiyo ; 40(10): 925-9, 1994 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-7992710

RESUMEN

We analyzed the sensitizing activity of five agents, which have been assumed to be MDR-overcoming drugs, in two human renal cell carcinoma cell lines expressing the MDR1 gene at high levels. In addition, we studied the sensitizing activity of cepharanthin, an MDR-overcoming agents, to vinblastine, adriamycin, epirubicin, cisplatin, mitomycin C and etoposide. Based on the results, we treated 6 patients with metastatic renal cell carcinomas (4: bones, 2: contralateral kidneys) by intraarterial injection of vinblastine and adriamycin (or epirubicin) in combination with cepharanthin. Two of the 4 bone metastasis cases responded markedly to the treatment. Renal tubular impairment was observed in one patient who was treated for the contralateral kidney metastasis.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/secundario , Resistencia a Múltiples Medicamentos/genética , Neoplasias Renales/patología , Alcaloides/administración & dosificación , Bencilisoquinolinas , Doxorrubicina/administración & dosificación , Humanos , Infusiones Intraarteriales , Neoplasias Renales/genética , Vinblastina/administración & dosificación
9.
Hinyokika Kiyo ; 40(2): 127-30, 1994 Feb.
Artículo en Japonés | MEDLINE | ID: mdl-8128922

RESUMEN

A 52-year-old woman with asymptomatic gross hematuria visited a hospital, where computed tomography and ultrasonography revealed a left suprarenal mass, which was diagnosed as adrenal myelolipoma. After two years observation, she was admitted to our hospital due to enlargement of the tumor, and left adrenalectomy was performed. The tumor consisted of two separate masses with different macroscopic appearances. One was type I, while the other was type II according to Soos' classification. We found no similar case in the literature. We added a review of 119 cases of surgically resected adrenal myelolipoma in Japan.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/patología , Mielolipoma/patología , Femenino , Humanos , Persona de Mediana Edad
10.
Hinyokika Kiyo ; 47(1): 1-4, 2001 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-11235213

RESUMEN

The role of the periodical bladder biopsy after transurethral resection (TUR-Bt) of superficial bladder cancer (sBT) was evaluated. Sixty-four patients (85 TURs) with sBT who underwent TUR-Bt between 1993 and 1998 were divided into 14 (22 TURs) who had carcinoma in situ (CIS) at the first TUR (group A), and 50 (64 TURs) who had papillary tumors without concomitant CIS (group B). Post-TUR intravesical instillation was performed with bacillus Calmette-Guerin for the majority of group A, and mitomycin C for the majority of group B. The first biopsy was performed at 3 months postoperatively, and the second biopsy was done at 8 to 12 months postoperatively. The mean observation time was 4 years and 6 months. Residual cancer was detected in 7 out of 34 biopsies (20.6%) in group A, and 19 out of 94 (20.2%) in group B. Every residual lesion in group A was CIS with negative cytology. In group B, with exclusion of 11 recurrent papillary tumors, the detection rate was only 8/83 (9.6%). In both groups, even in the cases with no sign of disease in biopsies, the recurrence immediately after the termination of the biopsy protocol was common. The progression of the cancer was more frequent in group A (4 patients), than in group B (2 patients) (p < 0.01, log-rank test), and no case in group B showed local progression. The periodical biopsy may have a certain, but limited advantage over conventional examinations. A less invasive and more sensitive method in awaited.


Asunto(s)
Biopsia/métodos , Carcinoma in Situ/prevención & control , Carcinoma de Células Transicionales/prevención & control , Recurrencia Local de Neoplasia/prevención & control , Neoplasias de la Vejiga Urinaria/prevención & control , Carcinoma in Situ/patología , Carcinoma de Células Transicionales/patología , Carcinoma de Células Transicionales/cirugía , Femenino , Humanos , Masculino , Recurrencia Local de Neoplasia/patología , Neoplasia Residual , Sensibilidad y Especificidad , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/cirugía , Procedimientos Quirúrgicos Urológicos
11.
Hinyokika Kiyo ; 43(9): 655-9, 1997 Sep.
Artículo en Japonés | MEDLINE | ID: mdl-9365846

RESUMEN

Two cases of renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator (t-PA) are reported. A 74-year-old woman with atrial fibrillation presented with left flank pain of 54-hour duration. Selective renal angiography revealed embolic obstruction of multiple segmental arteries in the left kidney. She was treated by one-shot intra-arterial t-PA infusion (8,000,000 units) and intravenous heparinization (25,000 units/3 days). Although fibrinolysis was successful except for most distal arterial branches, complete recovery of renal function was not obtained. A 66-year-old man presented with complete obstruction of left main renal artery. He had hyperthyroidism and atrial fibrillation. At 75 hours after onset of left flank pain, he was treated by one-shot intra-arterial t-PA infusion (18,000,000 units) and intravenous heparinization (4,000 units/24 hours). His renal function was recovered completely. Selective intraarterial t-PA infusion is considered an effective treatment for renal artery embolism.


Asunto(s)
Embolia/tratamiento farmacológico , Activadores Plasminogénicos/administración & dosificación , Arteria Renal , Activador de Tejido Plasminógeno/administración & dosificación , Anciano , Femenino , Humanos , Infusiones Intraarteriales , Masculino , Obstrucción de la Arteria Renal/tratamiento farmacológico , Terapia Trombolítica
12.
Hinyokika Kiyo ; 46(4): 229-34, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10845152

RESUMEN

A clinico-pathological study was performed retrospectively on 62 patients who underwent surgery for renal cell carcinoma between January 1992 and October 1998 at Himeji National Hospital to clarify the prognostic determinants for survival. The median follow-up period was 32 months and the cause-specific survival rates at 1, 3 and 5 years were 86.7, 81.3, 81.3%, respectively. Of the 62 patients, 11 (17.7%) patients died of renal cell carcinoma and 2 (3.2%) patients died of unrelated causes. Of the variables related to survival, presenting symptoms, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), tumor size, pathological tumor grade, infiltration pattern, pathological tumor stage, N classification and M classification were significant risk factors for survival by univariate analysis. However, ALP, N classification and M classification were significant for survival as determined by the step-wise procedure and M classification was the most significant factor according to Cox's proportional hazard model analysis.


Asunto(s)
Carcinoma de Células Renales/cirugía , Neoplasias Renales/cirugía , Adulto , Anciano , Carcinoma de Células Renales/clasificación , Carcinoma de Células Renales/patología , Femenino , Estudios de Seguimiento , Hospitales Públicos , Humanos , Japón , Neoplasias Renales/clasificación , Neoplasias Renales/patología , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estadificación de Neoplasias , Nefrectomía , Pronóstico , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo
13.
Hinyokika Kiyo ; 44(4): 253-7, 1998 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-9617621

RESUMEN

To study the efficacy and the safety of intravesical bacillus Calmette-Guerin (BCG) therapy for very elderly patients with superficial bladder cancer, we retrospectively compared patients over 80 years old who had received BCG therapy at our department between 1991 and 1996 (Group A; 10 patients 11 courses), with those below 80 years old (Group B, 17 patients 18 courses). In these patients, skin test reactivity to purified protein derivative showed a significant negative correlation with age (p = 0.016). No irreversible complications were observed in any patient. Persistence of acid-fast bacilli for more than one month after the termination of the course was observed in two patients in group A, and one in group B. A comparison of the cases undergoing eradicational BCG therapy in the two groups, grade 2 transitional cell carcinoma (TCC) was significantly more predominant than grade 3 TCC in group A (p = 0.004). (None of the tumors in group A were of grade 3) The disease-free rate was significantly lower in group A (p < 0.05), but 5 of the 10 patients in this group were finally disease-free. From these results, we conclude that intravesical BCG instillation therapy can be performed in patients over 80 years old, although a relatively lower disease-free rate is expected and special attention should be taken with regard to persistent BCG infection. The lower disease-free rate could be attributable to either diminished cellular immunity or a difference in tumor grade, although a definite conclusion could not be obtained here.


Asunto(s)
Vacuna BCG/administración & dosificación , Carcinoma de Células Transicionales/terapia , Neoplasias de la Vejiga Urinaria/terapia , Administración Intravesical , Anciano , Carcinoma de Células Transicionales/inmunología , Femenino , Humanos , Masculino , Estudios Retrospectivos , Prueba de Tuberculina , Neoplasias de la Vejiga Urinaria/inmunología
14.
Nihon Hinyokika Gakkai Zasshi ; 91(5): 520-5, 2000 May.
Artículo en Japonés | MEDLINE | ID: mdl-10853334

RESUMEN

BACKGROUND: There are many controversies surrounding the management of ectopic ureteroceles (EUC). The aim of this study is to review our cases with EUCs and to show our policy of choice of treatments of EUCs. METHODS: The medical records of 39 patients with EUCs treated at Kobe. Children's Hospital from 1978 to 1998 were reviewed retrospectively. Patients' age, affected site, presentation, treatment, and postoperative course were recorded. RESULTS: The age at presentation ranged from 0 month to 13 years (mean; 6 years). The left EUCs were found in 15 patients, the right in 17 patients, and the bilateral in 7 patients. The EUCs with duplicated system of the kidney were involved in 35 cases (42 kidneys) and single system in 4 cases (4 kidneys). The most common mode of presentation was urinary tract infection (n = 24) followed by abdominal distention (n = 6) and fetal ultrasonography (n = 6). One patient presented with incontinence and in two patients EUCs were discovered incidentaly. Thirty-five cases (42 kidneys) were followed up over six months. In these cases diversion including nephrostomy and ureterostomy was performed in 5 kidneys, heminephrectomy and/or excision of the EUC and ureteral reimplantation in 8 kidneys, nephrectomy in 3 kidneys, pyeloureterostomy in 2 kidneys, excision of the EUC and ureteral reimplantation in 10 kidneys, and transurethral incision (TUI) of the EUC in 14 kidneys. After these treatments the second surgery was totally required in 15 kidneys(36%) including 7 kidneys in which TUI was performed. Furthermore, in two kidneys the third operation was performed. CONCLUSIONS: Reoperation was required in about one-third of patients with ectopic ureteroceles. It is easy to perform TUI, however the rate to reoperation is high.


Asunto(s)
Ureterocele/cirugía , Adolescente , Anastomosis Quirúrgica , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Pelvis Renal/cirugía , Masculino , Nefrectomía , Reoperación/estadística & datos numéricos , Estudios Retrospectivos , Uréter/anomalías , Uréter/cirugía , Ureterocele/complicaciones , Derivación Urinaria , Infecciones Urinarias/complicaciones
15.
Nihon Hinyokika Gakkai Zasshi ; 89(3): 421-5, 1998 Mar.
Artículo en Japonés | MEDLINE | ID: mdl-9577557

RESUMEN

BACKGROUND: To achieve optimum drug delivery of Interferon-alpha in treatment of renal cell carcinoma, a regimen consisting of its daily intramuscular administration, in combination with oral fluorouracil, was designed and carried out. Its efficacy is examined retrospectively. METHODS: In our department 7 patients with disseminated renal cell carcinoma were treated with daily intramuscular injection of interferon-alpha (3 x 10(6) IU) and daily oral administration of fluorouracil. All patient was nehprectomized before initiation of the regimen. RESULTS: Two patients achieved complete, and three patients achieved partial response radiographically (Overall response rate 71%). Metastatic sites of responders were lung (4) and pleura (2). The time required until response was 3.9 (median 5.4) months. In two responders, new lesions appeared in other organs despite durable response in initial pulmonary metastatic sites. There were two no-responders, one patient is alive with stable disease and the other patient died for progression of the disease. In all, two patients died of disease, one died for other cause, one surviving without evidence of disease, and three are surviving with disease. No significant side effect was noted in these seven patients. CONCLUSIONS: This regimen can be carried out on outpatient basis and considerable response can be expected for pulmonary and pleural lesions.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Renales/terapia , Neoplasias Renales/terapia , Administración Oral , Adulto , Carcinoma de Células Renales/secundario , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Inyecciones Intramusculares , Interferón-alfa/administración & dosificación , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Neoplasias Pleurales/secundario , Neoplasias Pleurales/terapia , Resultado del Tratamiento
17.
Oncogene ; 31(25): 3098-110, 2012 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-22020339

RESUMEN

Inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene causes both hereditary and sporadic clear-cell renal-cell carcinoma (ccRCC). Although the best-characterized function of the VHL protein (pVHL) is regulation of hypoxia-inducible factor-α (HIFα), pVHL also controls the development of pheochromocytoma through HIF-independent pathways by regulating JunB. However, it is largely unknown how these pathways contribute to the development and progression of ccRCC. In the present study, we confirmed that JunB was upregulated in VHL-defective ccRCC specimens by immunostaining. Short-hairpin RNA (shRNA)-mediated knockdown of JunB in 786-O and A498 VHL null ccRCC cells suppressed their invasiveness. In addition, JunB knockdown significantly repressed tumor growth and microvessel density in xenograft tumor assays. Conversely, forced expression of wild-type, but not dimerization-defective, JunB in a VHL-restored 786-O subclone promoted invasion in vitro and tumor growth and vessel formation in vivo. Quantitative PCR array analysis revealed that JunB regulated multiple genes relating to tumor invasion and angiogenesis such as matrix metalloproteinase-2 (MMP-2), MMP-9 and chemokine (C-C motif) ligand-2 (CCL2) in 786-O cells. JunB knockdown in these cells reduced the proteolytic activity of both MMPs in gelatin zymography and the amount of CCL2 in the culture supernatant. Moreover, shRNA-mediated knockdown of MMP-2 or inhibition of CCL2 activity with a neutralizing antibody repressed xenograft tumor growth and angiogenesis. Collectively, these results suggest that JunB promotes tumor invasiveness and enhances angiogenesis in VHL-defective ccRCCs.


Asunto(s)
Carcinoma de Células Renales/metabolismo , Neoplasias Renales/metabolismo , Neovascularización Patológica/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Proteína Supresora de Tumores del Síndrome de Von Hippel-Lindau/metabolismo , Animales , Carcinoma de Células Renales/irrigación sanguínea , Carcinoma de Células Renales/patología , Humanos , Neoplasias Renales/irrigación sanguínea , Neoplasias Renales/patología , Ratones , Invasividad Neoplásica , Trasplante de Neoplasias , Proteínas Proto-Oncogénicas c-jun/genética , Trasplante Heterólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA